Skip to main content

Table 2 Univariate and multivariate Cox regression analysis of included variables for OS in training cohort

From: Development and validation of a prognostic nomogram for predicting overall survival in patients with primary bladder sarcoma: a SEER-based retrospective study

Characteristics

Univariate analysis

Multivariate analysis

HR (95% CI)

P-value

HR (95% CI)

P-value

Age

18–29

Reference

 

Reference

 

30–39

0.53 (0.27, 1.03)

0.06

0.48 (0.24, 0.96)

0.039*

40–49

0.56 (0.31, 1.03)

0.062

0.43 (0.23, 0.80)

0.008*

50–59

0.71 (0.41, 1.2)

0.202

0.74 (0.42, 1.27)

0.274

60–69

0.58 (0.35, 0.97)

0.039*

0.55 (0.32, 0.94)

0.030*

70–79

0.65 (0.4, 1.06)

0.081

0.62 (0.37, 1.03)

0.063

 ≥ 80

0.66 (0.4, 1.07)

0.094

0.61 (0.37, 1.03)

0.063

Sex

Female

Reference

   

Male

1.1 (0.92, 1.32)

0.308

  

Race

White

Reference

   

Black

1.07 (0.79, 1.46)

0.657

  

Other

1.11 (0.68, 1.8)

0.681

  

Marital status

Married

Reference

   

Single

0.9 (0.75, 1.08)

0.275

  

Unknown

1.07 (0.61, 1.87)

0.806

  

Pathological classification

Carcinosarcoma

Reference

 

Reference

 

Leiomyosarcoma

0.99 (0.79, 1.25)

0.927

0.79 (0.61, 1.03)

0.086

Sarcoma

1.55 (1.16, 2.07)

0.003*

1.36 (0.99, 1.88)

0.060

Spindle cell sarcoma

1.14 (0.7, 1.84)

0.602

0.94 (0.56, 1.60)

0.829

Other

1.3 (1, 1.69)

0.051

1.10 (0.83, 1.46)

0.510

Histological grade

Well differentiated

Reference

   

Moderately differentiated

1.35 (0.71, 2.57)

0.355

  

Poorly differentiated

1.19 (0.69, 2.07)

0.534

  

Undifferentiated

1.28 (0.74, 2.21)

0.381

  

Unknown

1.25 (0.72, 2.15)

0.426

  

T-stage

Ta

Reference

 

Reference

 

Tis

15.53 (2.11, 114.23)

0.007*

40.68 (5.17, 319.99)

 < 0.001*

T1

2.08 (1.35, 3.21)

 < 0.001*

2.20 (1.29, 3.75)

0.004*

T2

2.18 (1.48, 3.22)

 < 0.001*

2.07 (1.33, 3.23)

0.001*

T3

1.0051 (0.65, 1.57)

0.982

1.15 (0.68, 1.96)

0.595

T4

1.02 (0.64, 1.62)

0.926

1.17 (0.67, 2.06)

0.574

Unknown

1.86 (1.36, 2.56)

 < 0.001*

2.17 (1.45, 3.25)

 < 0.001*

N-stage

No

Reference

 

Reference

 

Yes

0.62 (0.48, 0.8)

 < 0.001*

0.74 (0.56, 0.97)

0.028*

Unknown

0.83 (0.68, 1.02)

0.084

1.03 (0.71, 1.50)

0.869

M-stage

No

Reference

 

Reference

 

Yes

2.7 (2.05, 3.55)

 < 0.001*

2.74 (2.00, 3.75)

 < 0.001*

Unknown

0.87 (0.69, 1.08)

0.205

0.85 (0.62, 1.19)

0.360

Tumor size

 < 4.8

Reference

 

Reference

 

 ≥ 4.8

2 (1.51, 2.63)

 < 0.001*

2.02 (1.52, 2.69)

 < 0.001*

Unknown

1.86 (1.44, 2.41)

 < 0.001*

2.11 (1.59, 2.81)

 < 0.001*

Surgical treatment

No

Reference

   

Yes

0.84 (0.57, 1.23)

0.364

  

Unknown

0.84 (0.56, 1.25)

0.396

  

Radiation

No/Unknown

Reference

   

Yes

1.39 (1.06, 1.81)

0.017*

1.26 (0.94, 1.70)

0.118

Chemotherapy

No/Unknown

Reference

   

Yes

0.97 (0.75, 1.26)

0.842

  
  1. *P < 0.05 indicating statistical significance
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us